WASHINGTON, D.C. – Cardiovascular Revascularization Medicine (CRM), the official journal of the annual Cardiovascular Research Technologies (CRT) meeting, has received its first Journal Impact Factor from Clarivate, 1.7. To receive an Impact Factor, journals had to meet all 24 criteria from the Web of Science. Only 15% of journals reviewed pass this measure. The quality criteria include the quality of the editorial content, such as consistent peer review, consistent peer-reviewed publications by editorial board members, and adherence to recognized standards adopted by academic societies. The Impact Factor also measures the “impact” of articles that appear in peer-reviewed journals, which takes into account the citation history of authors whose manuscripts are published in the journal and significance of the content published in the journal. “Receiving an Impact Factor is a huge milestone for the CRM journal,” Editor-in-Chief Ron Waksman, MD, said. “This rating establishes a baseline. From here, we only expect to grow as the quality of the manuscripts we publish continues to improve.” For context, another measure of the journal’s impact, known as the CiteScore, gives CRM a score of 3, which is an improvement from 2.6 in 2022. CiteScore is more closely based on citations of articles published in peer-reviewed journals. measures the average citations received per peer-reviewed document published in a journal.